Paolo Tarantino: Are all residual diseases equal?

Paolo Tarantino shared on LinkedIn:

“ Patients with residual breast cancer after neoadjuvant treatment harbor an increased risk of recurrence. But are all residual diseases equal?

In this JAMA Oncology review article, we dissect the anatomical, biological and immunological heterogeneity of residual disease, suggesting an experimental framework to potentially improve treatment tailoring.”

Source: Paolo Tarantino/LinkedIn

Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer

Authors: Paolo Tarantino, Gabriel Hortobagyi, Sara M. Tolaney, and Elizabeth A. Mittendorf

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.